Table 1 Patients characteristics
From: SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
|  | Mean ± SD or n/N (%) |
|---|---|
Age (years) | 60.3 ± 7.6 |
Female gender | 23/58 (39.0) |
Body weight (kg) | 87.6 ± 13 |
Height (cm) | 171 ± 11 |
BMI (kg/m2) | 29.8 ± 4.3 |
Mean duration of diabetes (years) | 5.54 ± 4.9 |
HbA1c (%) | 6.67 ± 0.7% |
Blood glucose concentration | |
 Fasting (mg/dl) | 132 ± 28 |
 Postprandiala (mg/dl) | 178 ± 66 |
Office blood pressure | |
 Systolic (mmHg) | 130 ± 13 |
 Diastolic (mmHg) | 80 ± 9.4 |
 Heart rate (bpm) | 69 ± 11 |
24Â h ambulatory blood pressure | |
 Systolic (mmHg) | 129 ± 12 |
 Diastolic (mmHg) | 77 ± 9 |
 Heart rate (bpm) | 74 ± 11 |
Haematocrit (%) | 40.1 ± 2.7 |
Serum sodium concentration (mmol/l) | 138.6 ± 2.0 |
Urinary sodium excretion over 24 h (mmol/day) | 216 ± 81 |